Raphael Pharmaceutical Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAPH research report →
Companywww.raphaelpharmaceutical.com
Raphael Pharmaceutical Inc. , a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis.
- CEO
- Shlomo Pilo
- IPO
- 2023
- HQ
- Jaffa, IL
Price Chart
Valuation
- Market Cap
- $28.25M
- P/E
- -23.98
- P/S
- 0.00
- P/B
- -16.53
- EV/EBITDA
- -24.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 84.78%
- ROIC
- 68.23%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $0 · 100.00%
- EPS
- $0.07 · 186.10%
- Op Income
- $0
- FCF YoY
- 60.53%
Performance & Tape
- 52W High
- $1.40
- 52W Low
- $0.05
- 50D MA
- $1.40
- 200D MA
- $1.03
- Beta
- 3.18
- Avg Volume
- 85.856
Get TickerSpark's AI analysis on RAPH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 20, 25 | Louria Hayon Igal | other | 350,000 |
| Nov 20, 25 | Louria Hayon Igal | other | 350,000 |
| Aug 1, 25 | Laor Zvi Laufer | other | 0 |
| Mar 10, 25 | Eliya Yehuda | other | 200,000 |
| May 12, 22 | Eliya Yehuda | other | 202,000 |
| Mar 2, 25 | Pilo Shlomo | other | 200,000 |
| Mar 2, 25 | Pilo Shlomo | other | 100,000 |
| Mar 5, 25 | Dhadha Ajay Kumar | other | 350,000 |
| Mar 5, 25 | Dhadha Ajay Kumar | other | 250,000 |
| Jan 8, 25 | Dhadha Ajay Kumar | other | 0 |
Our RAPH Coverage
We haven't published any research on RAPH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RAPH Report →